AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Skye Bioscience, Inc. Director's Dealing 2019

Aug 23, 2019

34097_dirs_2019-08-23_9cd238b2-b54b-49e3-acab-dae51b77dad7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emerald Bioscience, Inc. (EMBI)
CIK: 0001516551
Period of Report: 2019-08-21-06:00

Reporting Person: KIM DENNIS D (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-08-21-06:00	Employee Stock Options (Right to Buy)	$0.30	A	736541	Acquired	2029-08-21-06:00	Common Stock (736541)	Direct

Footnotes

F1: 25% of the options shall vest 90 days from the date of grant and the remaining 75% shall vest 1/33rd on each of the next 33 months thereafter.